Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1076 - 1100 of 2615 in total
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
Investigational
LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.
Investigational
AMY-101, also known as compstatin 40, is a peptidic inhibitor of the central complement component C3. AMY-101 is under investigation in clinical trial NCT03694444 (A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis).
Investigational
Matched Iupac: … carbamimidamidopropyl)-4-{[(1S,2S)-1-carbamoyl-2-methylbutyl](methyl)carbamoyl}-25-(2-carbamoylethyl)-10
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
SER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension).
Investigational
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Iupac: … ^{2,8}.0^{1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-16-yl]-3,3-dimethylbutan-2-ol ... {1,6}.0^{6,14}.0^{7,12}]icosa-7(12),8,10-trien-11-yl]oxy}ethoxy)-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1 ... cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1^{2,8}.0^ …
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
Investigational
Investigational
Investigational
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
Investigational
ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
Investigational
Matched Description: … ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target …
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
MDR-101 is a CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells
Investigational
AMT-101 is a recombinant human interleukin-10 fusion protein.
Investigational
Matched Synonyms: … Recombinant human interleukin-10 fusion protein …
Matched Description: … AMT-101 is a recombinant human interleukin-10 fusion protein. …
OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational
Investigational
Bi104 is being investigated for the treatment of Angelman syndrome.
Investigational
N-oleoyldopamine (OLDA) is an amide of dopamine and oleic acid.
Investigational
Matched Synonyms: … (9z)- n-(2-(3,4-dihydroxyphenyl)ethyl)-9-octadecenamide …
Matched Iupac: … (9Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamide …
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Matched Iupac: … (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene …
Experimental
Matched Synonyms: … (Z)-9-hexadecenoic acid ... 9-cis-hexadecenoic acid ... (Z)-hexadec-9-enoic acid …
Matched Iupac: … (9Z)-hexadec-9-enoic acid …
Investigational
Matched Synonyms: … trimetheno-12H-pyrimido[5,4-j][1,9,2,5,17]dithiatriazacyclotricosin-19-one, 17-fluoro-20,21-dihydro-10
Matched Iupac: … {4,9}]hentriaconta-1(27),2(31),4(9),5,7,10,12,17(29),18,20,24(28),25-dodecaene-16,22,22-trione ... -31-methyl-3,22lambda6,30-trithia-6,8,15,23,26-pentaazahexacyclo[22.3.1.1^{2,5}.1^{10,13}.1^{17,21}.0^ …
Displaying drugs 1076 - 1100 of 2615 in total